Authors: Hejdeman, B Lenkei, R Leandersson, AC Hultstrom, AL Wahren, B Sandstrom, E Bratt, G

Citation: B. Hejdeman et al., Clinical and immunological benefits from highly active antiretroviral therapy in spite of limited viral load reduction in HIV type 1 infection, AIDS RES H, 17(4), 2001, pp. 277-286

Authors: O'Meara, D Wilbe, K Leitner, T Hejdeman, B Albert, J Lundeberg, J

Citation: D. O'Meara et al., Monitoring resistance to human immunodeficiency virus type 1 protease inhibitors by pyrosequencing, J CLIN MICR, 39(2), 2001, pp. 464-473

Authors: De Milito, A Hejdeman, B Albert, J Aleman, S Sonnerborg, A Zazzi, M Chiodi, F

Citation: A. De Milito et al., High plasma levels of soluble Fas in HIV type 1-infected subjects are not normalized during highly active antiretroviral therapy, AIDS RES H, 16(14), 2000, pp. 1379-1384

Authors: Hulstrom, AL Hejdeman, B Leandersson, AC Bratt, G Carbone, E Wahren, B

Citation: Al. Hulstrom et al., Human natural killer cells in asymptomatic human immunodeficiency virus-1 Infection, INTERVIROLO, 43(4-6), 2000, pp. 294-301

Authors: Van Vaerenbergh, K Van Laethem, K Albert, J Boucher, CAB Clotet, B Floridia, M Gerstoft, J Hejdeman, B Nielsen, C Pannecouque, C Perrin, L Pirillo, MF Ruiz, L Schmit, JC Schneider, F Schoolmeester, A Schuurman, R Stellbrink, HJ Stuyver, L Van Lunzen, J Van Remoortel, B Van Wijngaerden, E Vella, S Witvrouw, M Yerly, S De Clercq, E Desmyter, J Vandamme, AM

Citation: K. Van Vaerenbergh et al., Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues, ANTIM AG CH, 44(8), 2000, pp. 2109-2117